Irdabisant

Irdabisant, assigned the development code CEP-26401, is a synthetic small molecule of the pyridazinone chemical class that acts as an antagonist and inverse agonist at the histamine H3 receptor ^[1]. It was designed as a candidate for treating attentional and cognitive disorders and was noted for its favorable drug-like properties, including good water solubility, brain penetration, and low potential for drug interactions ^[1]. The compound was developed by Cephalon, a company later acquired by Teva Pharmaceutical ^[3].

The histamine H3 receptor had become an attractive target for cognition-enhancing drugs because blocking it boosts the brain's release of several neurotransmitters that support alertness and learning ^[2]. Irdabisant emerged from a medicinal-chemistry program that optimized a series of pyridazinone H3 antagonists, and it was selected as the lead candidate on the strength of its high affinity, strong selectivity, and safety profile in preclinical testing ^[1]. Related structural analogues were also explored in efforts to refine the series further ^[4].

In laboratory and animal models, irdabisant enhanced short-term memory, promoted wakefulness, and showed effects suggesting possible usefulness in schizophrenia, both alone and as an add-on to existing antipsychotics ^[2]. It then progressed into human testing, where single-dose and repeat-dose studies in healthy volunteers characterized its pharmacokinetics and effects; it was slowly absorbed, stayed in the body for a long time, and had a dose-related tendency to disturb sleep while improving some cognitive measures at lower levels ^[3]. The drug was generally well tolerated, with headache and insomnia being the most common side effects ^[3].

Despite this early promise, irdabisant was not developed into an approved medicine and remains an investigational compound rather than a marketed drug ^[3]. Its human studies concluded that further clinical work would be needed to establish whether low doses could enhance cognition, but it did not advance to widespread use ^[3]. Today it is primarily of interest as a research tool and as an example of histamine H3-targeted drug development ^[1].

Investigational, not approved. H3 antagonists as a class tend to cause insomnia (unsurprisingly, since they promote wakefulness) and sometimes headache or GI effects; taking it too late in the day is the obvious mistake. Human data on irdabisant specifically is early-stage. Research use only; the closest approved cousin is pitolisant.